questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de la phospholipase A2
Inhibiteurs de la phospholipase A2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Phospholipases
Tests de laboratoire
Tests de laboratoire
Acides gras
Imagerie médicale
Diagnostic
Symptômes
5
Troubles digestifs
Symptômes
Éruptions cutanées
Inflammation
Prévention
5
Prévention
Alimentation équilibrée
Compléments alimentaires
Anti-inflammatoires
Traitements
5
Médicaments anti-inflammatoires
Inhibiteurs
Corticostéroïdes
Inflammation
Plantes médicinales
Traitements naturels
Complications
5
Maladies chroniques
Inflammation
Suivi médical
Gestion des complications
Facteurs de risque
5
Facteurs de risque
Prédispositions génétiques
Obésité
Facteurs de risque
Stress chronique
Inflammation
Antécédents familiaux
Maladies inflammatoires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la phospholipase A2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la phospholipase A2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-18",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "James A Shayman",
"url": "https://questionsmedicales.fr/author/James%20A%20Shayman",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu."
}
},
{
"@type": "Person",
"name": "Kathleen Fernandes Grego",
"url": "https://questionsmedicales.fr/author/Kathleen%20Fernandes%20Grego",
"affiliation": {
"@type": "Organization",
"name": "Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil."
}
},
{
"@type": "Person",
"name": "Akira Abe",
"url": "https://questionsmedicales.fr/author/Akira%20Abe",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu."
}
},
{
"@type": "Person",
"name": "Shulin Hou",
"url": "https://questionsmedicales.fr/author/Shulin%20Hou",
"affiliation": {
"@type": "Organization",
"name": "Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China."
}
},
{
"@type": "Person",
"name": "Junping Bai",
"url": "https://questionsmedicales.fr/author/Junping%20Bai",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Propensity score analysis with local balance.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37012676",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/sim.9741"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognostic score-based model averaging approach for propensity score estimation.",
"datePublished": "2024-10-03",
"url": "https://questionsmedicales.fr/article/39363252",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12874-024-02350-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "An overview of propensity score matching methods for clustered data.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36426585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/09622802221133556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Traumatic Injury in Pregnancy: A Propensity Score-Matched Analysis.",
"datePublished": "2022-12-12",
"url": "https://questionsmedicales.fr/article/36914991",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2022.10.087"
}
},
{
"@type": "ScholarlyArticle",
"name": "Parametric and nonparametric propensity score estimation in multilevel observational studies.",
"datePublished": "2023-08-02",
"url": "https://questionsmedicales.fr/article/37532119",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/sim.9852"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de la phospholipase A2",
"item": "https://questionsmedicales.fr/mesh/D064801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la phospholipase A2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la phospholipase A2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la phospholipase A2",
"description": "Comment diagnostiquer une inhibition de la phospholipase A2 ?\nQuels tests sont utilisés pour évaluer l'inhibition ?\nY a-t-il des marqueurs spécifiques pour l'inhibition ?\nL'imagerie est-elle utile dans ce diagnostic ?\nQuels symptômes peuvent indiquer une inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?\nL'inhibition provoque-t-elle des douleurs articulaires ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la phospholipase A2",
"description": "Comment prévenir l'inhibition de la phospholipase A2 ?\nLes exercices physiques aident-ils à prévenir l'inhibition ?\nY a-t-il des habitudes à éviter ?\nLes compléments alimentaires sont-ils utiles ?\nLa gestion du stress peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la phospholipase A2",
"description": "Quels traitements existent pour inhiber la phospholipase A2 ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements naturels disponibles ?\nComment les inhibiteurs spécifiques sont-ils administrés ?\nLes traitements nécessitent-ils un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la phospholipase A2",
"description": "Quelles complications peuvent survenir avec l'inhibition ?\nL'inhibition peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques d'allergies ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à l'inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les facteurs de risque d'inhibition ?\nL'obésité est-elle un facteur de risque ?\nLe stress chronique influence-t-il l'inhibition ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Propensity+Score#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition de la phospholipase A2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biochimiques mesurant l'activité de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inhibition ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages d'acides gras peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'inhibition ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs comme les cytokines peuvent indiquer une inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile dans ce diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est généralement pas utilisée pour diagnostiquer l'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une inhibition ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes inflammatoires comme la douleur ou le gonflement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, inflammation et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition provoque-t-elle des douleurs articulaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inhibition peut entraîner des douleurs articulaires dues à l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes digestifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles digestifs peuvent survenir, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la sensibilité individuelle."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison de l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition de la phospholipase A2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir l'inhibition."
}
},
{
"@type": "Question",
"name": "Les exercices physiques aident-ils à prévenir l'inhibition ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'inflammation et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut réduire le risque d'inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les compléments alimentaires sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments peuvent avoir des effets anti-inflammatoires, mais prudence."
}
},
{
"@type": "Question",
"name": "La gestion du stress peut-elle aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut réduire l'inflammation et améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour inhiber la phospholipase A2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation liée à l'inhibition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent avoir des effets inhibiteurs, mais peu prouvés."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs spécifiques sont-ils administrés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou injectable selon le médicament."
}
},
{
"@type": "Question",
"name": "Les traitements nécessitent-ils un suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies inflammatoires chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'allergies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir avec certains inhibiteurs de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'inhibition ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un ajustement du traitement sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'alimentation, le mode de vie et des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut augmenter le risque d'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il l'inhibition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber l'inflammation et l'inhibition."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies inflammatoires peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'inhibition peut augmenter avec l'âge en raison de l'inflammation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 13/03/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology, College of Korean Medicine, Kyung Hee University, 26-6 Kyungheedae-ro, Dongdamoon-gu, Seoul 02453, Korea.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Departamento de Química, Universidade Federal de Lavras/UFLA, Campus Universitário, Caixa Postal 3037, 37200-000 Lavras, MG, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Departamento de Bioquímica, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Inhibiteurs de la phospholipase A2" :
Most propensity score (PS) analysis methods rely on a correctly specified parametric PS model, which may result in biased estimation of the average treatment effect (ATE) when the model is misspecifie...
Propensity scores (PS) are typically evaluated using balance metrics that focus on covariate balance, often without considering their predictive power for the outcome. This approach may not always res...
We conduct a series of simulations alongside an analysis of empirical observational data to compare the performances of weighted treatment effect estimates using the proposed and existing approaches. ...
The simulation and empirical data analysis reveal that our proposed model-averaging approaches for PS estimation consistently yield lower bias and less variability in treatment effect estimates across...
The prognostic score-based model averaging approach for estimating PS can outperform existing model averaging methods. In particular, the estimator using the model averaging prognostic score as a bala...
Using the prognostic score as the balance metric for the PS model averaging enhances the performance of the treatment effect estimator, which can be recommended for a wide variety of situations. When ...
Propensity score matching is commonly used in observational studies to control for confounding and estimate the causal effects of a treatment or exposure. Frequently, in observational studies data are...
Trauma represents the leading cause of nonobstetrical maternal death. How in-hospital outcomes of acutely injured pregnant patients (PP) compares to that of similarly aged nonpregnant control groups (...
The American College of Surgeons Trauma Quality Improvement Program (TQIP) was used to identify traumatically injured females between 2017 and 2019. Propensity score matching on age, race, injury seve...
A total of 1078 traumatically injured pregnant females were identified. Propensity score matching resulted in 990 patients in the PP and CG cohorts. After matching, PPs were more likely to be assault ...
After acute trauma, PPs did not have increased mortality or complications when compared to matched controls, although they were more likely to be victims of assault, directly proceed to the OR, requir...
There has been growing interest in using nonparametric machine learning approaches for propensity score estimation in order to foster robustness against misspecification of the propensity score model....
Spouse bereavement is one of life's greatest stresses and has been suggested to trigger or accelerate cognitive decline and dementia. However, little information is available about the potential brain...
A total of 319 ever-married older adults between the ages of 61 and 90 years underwent comprehensive clinical assessments and multimodal brain imaging including [...
Spouse bereavement was significantly associated with higher cerebral white matter hyperintensity (WMH) volume compared with no spouse bereavement. Interaction and subsequent subgroup analyses showed t...
The findings suggest that the spouse bereavement may contribute to dementia or cognitive decline by increasing cerebrovascular injury, particularly in older individuals and those with no- or low-skill...
Propensity score weighting is a useful tool to make causal or unconfounded comparisons between groups. According to the definition by the Institute of Medicine (IOM), estimates of health care disparit...
The present study introduces a deweighting method that uses two types of propensity scores. One is a function of all covariates of health status and SES variables and is used to weight study subjects ...
The procedure of deweighting is illustrated using a dataset from a right heart catheterization (RHC) study, where it was used to examine whether there was a disparity between black and white patients ...
Deweighting is a promising tool for implementing the IOM-definition of health care disparities. The method is expected to be broadly applied to quantitative research on health care disparities....
Liver resection (LR) is the only recommended effective curative treatment for patients with intrahepatic cholangiocarcinoma (ICC), but the prognosis of patients with ICC is still poor even after curat...
Many spatial phenomena exhibit interference, where exposures at one location may affect the response at other locations. Because interference violates the stable unit treatment value assumption, stand...
Propensity score methods are a popular approach to mitigating confounding bias when estimating causal effects in observational studies. When study units are clustered (eg, patients nested within healt...